, plus male condom * Intra-uterine system (IUS) levonorgestrel IUS (e.g., Mirena), plus male condom * Medroxyprogesterone injections (Depo-Provera) plus male condom * Etonogestrel implants (e.g., Implanon, Norplan) plus male condom * Normal and low dose combined oral contraceptive pills, plus male condom * Norelgestromin / ethinylestradiol transdermal system plus male
combined oral pills, norelgestromin / ethinylestradiol transdermal system, intravaginal device (eg, ethinylestradiol and etonogestrel ), desogestrel (eg, Cerazette™), total sexual abstinence and vasectomised sexual partner. Women should have been stable on their chosen method of birth control for a minimum of 3 months before entering the trial and should continue with birth control for 1 month after
OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free levonorgestrel-containing oral contraceptivessubjects in insurance claims database who were first time users of triphasic